Could Buying This Weight Loss Stock Be Like Investing in Novo Nordisk At The Dawn of The GLP-1 Revolution?
The Motley FoolNovo Nordisk dominates diabetes treatment and obesity care, but one clinical-stage pharma company could be the next breakout star.